Delivery Order HHSN261201500042I-HHSN26100002
Award Date 9/24/15
Potential Completion Date 9/23/18
Potential Value $596K
Federal Agency
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Chicago, IL 60616, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed price delivery order awarded by the National Cancer Institute (NCI) to IIT Research Institute (IITRI), a non-profit preclinical contract research organization (CRO). The contract is for $532,562.26 to evaluate a breast cancer prevention agent under the PREVENT Cancer Preclinical Drug Development Program, a $149.995 million NCI Indefinite Delivery Vehicle (IDV) that IITRI holds. IITRI has extensive experience providing preclinical drug development services to federal agencies...
- The National Cancer Institute awarded a $1.74 million firm fixed-price delivery order to IIT Research Institute (IITRI) on September 8, 2020, for preclinical development of an RNA vaccine for immunoprevention of prostate cancer under the PREVENT Preclinical Drug Development Program. The work, to be performed in Chicago, Illinois, is scheduled for completion by May 7, 2025, with no small business set-aside designation applied. IITRI, a non-profit contract research organization and subsidiary of...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $2,398.74 delivery order against the PREVENT Preclinical Drug Development Program indefinite-delivery/indefinite-quantity master contract to IIT Research Institute. IIT Research Institute, a subsidiary of the Illinois Institute Of Technology Sponsored Research And Programs Division, will provide a "CONTRACT ORIENTATION AND KICKOFF MEETING" as the prime contractor. The...
- The National Cancer Institute awarded a $1.89 million cost-plus-fixed-fee delivery order to IIT Research Institute (IITRI) on September 16, 2024, for toxicology studies in rats and dogs involving the experimental compound AIT-102. The work will be performed in Chicago, Illinois, with a completion date of June 30, 2026. This delivery order was issued under one of IITRI's existing indefinite delivery/indefinite quantity (IDIQ) contract vehicles with NCI—specifically the $149.995 million PREVENT...
- This federal contract award with award ID HHSN261201500024I|HHSN26100003 was issued by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services (HHS). The $321,110.80 award was made on September 15, 2016 to the IIT Research Institute (IITRI), a non-profit research organization and division of the Illinois Institute of Technology (IIT). The contract is for the "PRECLINICAL EVALUATION OF A NEW LIPID-BASED SMEDDS" under the NCI's PREVENT...
- The National Cancer Institute awarded a definitive cost-plus-fixed-fee contract to IIT Research Institute (IITRI), a non-profit contract research organization and subsidiary of the Illinois Institute of Technology, for preclinical toxicology and pharmacology services supporting drug development for cancer, AIDS, and AIDS-related illnesses. The contract, awarded on April 1, 2004, carries a ceiling value of $159.3 million with an ultimate completion date of June 30, 2016, and will be performed...
- This is a $718,265.00 delivery order awarded by the National Cancer Institute (NCI) of the Department of Health and Human Services (HHS) to IIT Research Institute, the research and technology development arm of Illinois Institute of Technology (IIT). The contract supports preclinical toxicology and pharmacology research for drugs developed for cancer patients, including exploratory studies of CCR4 CAR T cells. This work is performed under the NCI's "Toxicology of Drugs Developed for...
- This is a federal contract award to IIT Research Institute by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute. The $2,111,543.00 firm fixed price delivery order is for support related to the aerosol development of the drug bexarotene under the PREVENT Toxicology and Pharmacology Testing (PREVENT TOX) master indefinite delivery/indefinite quantity (IDIQ) contract. IIT Research Institute, the research and technology arm of Illinois...
- This federal contract award, valued at $33,483,214.15, was issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The contract is for preclinical pharmacology and toxicology studies to support the development of small molecule, biologic, and RNA therapeutic candidates across various disease areas. IITRI has extensive experience providing these services to...
- The National Cancer Institute awarded a $9.35 million cost-plus-fixed-fee contract to IIT Research Institute (IITRI) on April 1, 2022, for preclinical toxicology studies of large molecule drugs developed for cancer and other indications. The contract, which extends through March 31, 2029, will be performed in Chicago, Illinois. IITRI, a nonprofit contract research organization and subsidiary of Illinois Institute of Technology, will conduct comprehensive toxicological testing and safety...